PolyPid (NASDAQ:PYPD) Releases Earnings Results, Misses Expectations By $0.23 EPS

PolyPid (NASDAQ:PYPD) released its quarterly earnings results on Wednesday. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.23), Zacks reports.

PolyPid Stock Performance

PYPD stock traded down $0.01 during trading on Wednesday, hitting $2.88. 3,177 shares of the company’s stock traded hands, compared to its average volume of 22,427. The stock has a market capitalization of $29.35 million, a price-to-earnings ratio of -0.37 and a beta of 1.32. PolyPid has a 52 week low of $2.37 and a 52 week high of $7.00. The stock has a fifty day moving average price of $3.02 and a two-hundred day moving average price of $3.32. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17.

Analyst Ratings Changes

Several research firms have issued reports on PYPD. RODMAN&RENSHAW upgraded PolyPid to a “strong-buy” rating in a report on Tuesday, January 28th. HC Wainwright dropped their price target on shares of PolyPid from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, December 26th. Craig Hallum assumed coverage on shares of PolyPid in a report on Monday, November 4th. They set a “buy” rating and a $10.00 price objective for the company. Finally, Rodman & Renshaw began coverage on shares of PolyPid in a research report on Tuesday, January 28th. They issued a “buy” rating and a $13.00 target price for the company.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.